AI, Future Heman Health & Disease.

 AI, Future Human Health & Disease ‘What Are We Facing’?

AI ERA. 

Disease - protect brain health from NOW.

AI ERA. 

Disease - protect brain health from NOW.

A global health conversation for today before tomorrow becomes a diagnosis

Artificial intelligence is rapidly changing how people work, learn, communicate, make decisions and access information. The question is not whether AI is “good” or “bad.” The important public-health question is:

As human exposure to AI and digital environments increases, what changes in our brain, behaviour, sleep, physical activity and metabolic health should we detect early — before they become serious health problems?

The World Health Organization is already calling for longitudinal research into the effects of generative AI and digital environments on mental health and wellbeing. WHO has specifically identified concerns involving excessive use, isolation, sleep, sedentary behaviour, anxiety and depression, while emphasizing that the long-term effects of generative AI are still insufficiently understood.

World Health Organization +1

https://www.who.int/news-room/commentaries/detail/the-digital-choices-shaping-our-children-s-health?utm_source=chatgpt.com

 

https://www.who.int/news/item/20-03-2026-towards-responsible-ai-for-mental-health-and-well-being--experts-chart-a-way-forward?utm_source=chatgpt.com

 

🧠 THE WARNING MAY NOT BEGIN WITH A DIAGNOSIS

It may begin with small changes that people dismiss:

“I can't concentrate like before.”

“I keep forgetting things.”

“I feel mentally tired.”

“I am becoming more easily irritated.”

“My sleep isn't what it used to be.”

“I spend too much time on screens.”

“I don't feel like meeting people anymore.”

These are symptoms or risk indicators—not proof of disease.

That distinction is crucial.

WHO identifies memory problems, confusion, mood changes, social withdrawal and difficulties with thinking among possible early manifestations associated with cognitive impairment and dementia, while also identifying modifiable risk factors such as physical inactivity, poor sleep, diabetes, hypertension, obesity and social isolation.

World Health Organization

https://www.who.int/news-room/fact-sheets/detail/dementia?utm_source=chatgpt.com

 

So why wait until someone becomes a patient? 

AI ERA.

Disease - protect brain health from NOW.

The better public-health approach is:

NOTICE → MEASURE → ACT → MONITOR → SEEK MEDICAL CARE WHEN NEEDED

🌿 WHERE DOES KESUM FIT?

This is where KESUM (Persicaria minor / Biokesum®) becomes an interesting research-supported brain-health candidate.

A randomized, double-blind, placebo-controlled human study involving older adults with mild cognitive impairment found that six months of Biokesum® supplementation was associated with significant improvements in:

Visual memory

Tension

Anger

Confusion

Total negative mood subscales

BDNF

Triglycerides

The researchers concluded that Biokesum® potentially improved visual memory, negative mood, BDNF and triglycerides.

PubMed Central (PMC) +1

https://pmc.ncbi.nlm.nih.gov/articles/PMC7574246/?utm_source=chatgpt.com

 

The reported changes included approximately −18.7% confusion, −30.91% tension, −52.95% anger, −33.43% total negative mood subscales and −19.05% triglycerides, while BDNF increased 2.03% in the Biokesum® group.

PubMed Central (PMC) https://pmc.ncbi.nlm.nih.gov/articles/PMC7574246/?utm_source=chatgpt.com

 

 

That gives us an important scientific pathway:

EARLY SYMPTOM → BIOMARKER → INTERVENTION → MONITORING

Memory / confusion

↓

Cognitive assessment

Stress / negative mood

↓

Mood assessment

Brain-health pathway

↓

BDNF monitoring

Metabolic risk

↓

Triglyceride monitoring

Then: lifestyle + medical assessment + evidence-supported interventions where appropriate.

 

BUT KESUM SHOULD NOT BE PRESENTED AS A CURE

This is actually what makes the message more credible internationally.

The 2020 trial was conducted in 36 Malaysian adults aged 60–75 with MCI, with 30 completing the intervention. It provides human clinical evidence for particular measured outcomes but it does not establish that KESUM prevents Alzheimer's disease, dementia, or AI-related disease.

PubMed

https://pubmed.ncbi.nlm.nih.gov/33076878/

Therefore, the strongest message is:

“Don't wait for disease. Recognise the early warning signs, monitor brain health and act early.”

And:

“KESUM is a clinically studied botanical candidate for brain-health support—not a replacement for diagnosis or medical treatment.”

That is scientifically much stronger than making a disease-prevention claim.

🌍 THE 2026–2056 QUESTION

This could become a long-term international community-health story:

2026

Establish the baseline.

2030

Measure changes in AI/digital exposure, sleep, physical activity, mental health and cognition.

2035

Compare populations by age, sex and country.

2040

Determine whether persistent digital/AI behaviours are associated with measurable long-term health changes.

2045

Track people who showed early symptoms versus those who did not.

2050

Examine whether early interventions changed outcomes.

2056

After 30 years, we may finally have robust longitudinal evidence showing which relationships were genuine, which were temporary and which were unrelated to AI.

That is the scientific experiment the world has not yet completed.

🧠 THE KESUM QUESTION 

AI ERA. 

Disease - protect brain health from NOW.

Instead of asking:

“Can KESUM prevent dementia?”

Ask the scientifically testable question:

“Can early identification of cognitive and mood changes, combined with lifestyle intervention and evidence-supported nutritional approaches such as Biokesum®, help maintain brain-health indicators and potentially delay progression in at-risk individuals?”

That question can be tested.

And BDNF gives us one measurable biological pathway to investigate, rather than relying only on people's subjective feelings.

THE MESSAGE TO THE WORLD

AI is advancing faster than our understanding of its long-term effects on human health.

We should not wait 20 or 30 years to discover that early warning signs were ignored.

Memory changes.

Confusion.

Stress.

Negative mood.

Poor sleep.

Reduced physical activity.

Social withdrawal.

Metabolic changes.

These should be noticed, measured and investigated early.

KESUM — Persicaria minor / Biokesum® — already has human clinical research showing improvements in selected memory, mood, BDNF and triglyceride outcomes among older adults with MCI.

PubMed Central (PMC)

https://pmc.ncbi.nlm.nih.gov/articles/PMC7574246/?utm_source=chatgpt.com

The opportunity now is not to claim a cure.

The opportunity is to investigate whether early brain-health support can help people stay healthier for longer.

Don't wait until symptoms become a diagnosis.

NOTICE EARLY. MONITOR. ACT.

Science First. Everything Follows.

This framing also aligns with the 2026 WHO approach to dementia risk reduction, which emphasizes action before dementia develops including cognitive stimulation, physical activity, management of cardiometabolic risks and other modifiable factors. WHO estimates that up to 45% of dementia risk is attributable to potentially modifiable factors, while stressing that risk reduction is not the same as guaranteeing prevention. 

World Health Organization +1

https://www.who.int/news/item/15-07-2026-new-who-guidelines--up-to-45--of-dementia-risk-could-be-prevented-or-delayed?utm_source=chatgpt.com 

AI ERA. 

Disease - protect brain health from NOW.

AI ERA. 

Disease - protect brain health from NOW.

AI ERA. 

Disease - protect brain health from NOW.

A little note 🩷

Still available for now.

While stocks last.

WHILE STOCKS LAST

WHILE STOCKS LAST

WHILE STOCKS LAST

https://web.biotropicsmalaysia.com/zul  

PHYSTA® Tongkat Ali: 26 Clinical Studies on Testosterone, Energy, Immunity & Performance for Malaysia’s Uniformed Personnel.

PHYSTA® Tongkat Ali: 26 Clinical Studies on Testosterone, Energy, Immunity & Performance for Malaysia’s Uniformed Personnel.

The People Behind the uniform

THE UNIFORM IS A SYMBOL OF RESPONSIBILITY

THE PERSON INSIDE THE UNIFORM IS THE FIRST LINE OF READINESS

A uniform represents more than a profession.

It represents duty, discipline, courage and responsibility.

Whether Police, Army, Navy, Air Force or Customs, these men and women may be required to perform under pressure, maintain alertness, manage demanding schedules and remain physically prepared to respond when the nation needs them.

But behind every uniform is a human body.

And human performance begins with human health. 

The People Behind the uniform.

 

The People Behind the uniform.

TESTOSTERONE MANAGEMENT: PART OF THE PERFORMANCE EQUATION

Testosterone is not simply about masculinity or muscle.

Healthy testosterone levels are associated with important aspects of male physiology including muscle function, energy, body composition, sexual health and overall wellbeing.

Clinical research on Eurycoma longifolia has found evidence of increased total testosterone in several randomized clinical trials, although results vary between studies and more research is still required. A systematic review and meta-analysis identified nine clinical studies and five RCTs, with a significant overall increase in total testosterone.

PubMed +1 https://pubmed.ncbi.nlm.nih.gov/36013514/

 

The People Behind the uniform.

For PHYSTA®, a randomized, double-blind, placebo-controlled multicentre study involving 105 men aged 50–70 found that the 200 mg group had significant increases in total testosterone versus placebo at weeks 4, 8 and 12. The study also reported reductions in fatigue scores and improvements in muscle strength within the study period.

PubMed https://pubmed.ncbi.nlm.nih.gov/36013514/

 

This is where “testosterone management” becomes relevant to everyday wellbeing—not as a promise of unlimited energy, but as one component of maintaining healthy physiological function.

 

The People Behind the uniform. 

FROM ENERGY TO READINESS

The goal is not: “24 hours of unlimited energy.”

The more scientifically defensible message is:

SUPPORTING THE BODY'S CAPACITY TO STAY READY — DAY AFTER DAY.

A person on duty needs:

Energy → Focus → Strength → Stamina → Recovery → Resilience

And these depend on much more than a supplement:

Good nutrition + adequate sleep + physical training + stress management + healthy hormone balance + appropriate supplementation.

PHYSTA® can be positioned as a supportive component within that broader performance-health system.

IMMUNITY: ANOTHER IMPORTANT LAYER OF READINESS

This is particularly interesting for people whose responsibilities require them to remain operational despite demanding environments.

A randomized, double-blind, placebo-controlled study in middle-aged Japanese adults investigated 200 mg/day of PHYSTA® for four weeks. The study reported significantly higher Scoring of Immunological Vigor, immunological grade, total T cells and CD4+ T cells compared with placebo.

PubMed https://pubmed.ncbi.nlm.nih.gov/26816234/

 

The People Behind the uniform.

That gives us an important scientific story:

HEALTHY IMMUNE FUNCTION SUPPORTS HUMAN RESILIENCE.

But there is an important distinction.

Supporting immune parameters is not the same as preventing infection.

We should therefore not say that Nu-Prep or PHYSTA® can “block viruses,” “prevent dengue,” or guarantee protection from infectious disease.

WHAT ABOUT VIRUSES?

There is interesting preclinical evidence.

Researchers at the University of Malaya/TIDREC and collaborating institutions investigated PHYSTA® against dengue virus. In cell experiments, PHYSTA® demonstrated antiviral activity against DENV-1 through DENV-4; an animal model also showed reduced viral load and higher platelet counts in the extract group.

PubMed https://pubmed.ncbi.nlm.nih.gov/33597402/

 

A later 2024 study investigated PHYSTA® against SARS-CoV-2 in vitro and reported dose-dependent inhibition of viral replication. The researchers specifically stated that further animal and clinical studies were needed.

MySitasi +1 https://pubmed.ncbi.nlm.nih.gov/33597402/

 

The People Behind the uniform.

PHYSTA® has demonstrated promising antiviral activity in laboratory and preclinical research, but this does not establish that taking Tongkat Ali prevents or treats viral infection in humans.

WHY DOES THIS MATTER TO NATIONAL SERVICE?

HEALTH

↓

PHYSIOLOGICAL READINESS

↓

PHYSICAL & MENTAL PERFORMANCE

↓

DUTY READINESS

↓

PUBLIC SAFETY

↓

NATIONAL RESILIENCE

A police officer protecting the public.

A soldier defending the nation's sovereignty.

A sailor protecting maritime interests.

An airman maintaining operational readiness.

A customs officer protecting the country's borders and economic interests.

Their missions are different. Their responsibility is shared.

They need to maintain themselves so that, when the call comes, they are ready to perform their responsibility.

NU-PREP + PHYSTA®

SCIENCE FIRST. EVERYTHING FOLLOWS.

The real strength of PHYSTA® is not simply the word Tongkat Ali.

It is the effort to move from traditional knowledge toward:

Standardization → Clinical research → Human evidence → Responsible application

Biotropics currently describes PHYSTA® as supported by 26 clinical studies, covering areas including testosterone, stress, strength, fertility, quality of life, healthy ageing, immunity and metabolic health.

Biotropics Malaysia

https://www.biotropicsmalaysia.com/research/clinical-study-physta?utm_source=chatgpt.com

 

The People Behind the uniform.

26 CLINICAL STUDIES. 1 STANDARDIZED EXTRACT. 0 GUESSWORK.

“You train to protect the nation.

You maintain your health to remain ready.

Science helps you make informed choices about that preparation.”

THE FINAL STORY

They wear the uniform.

They carry the responsibility.

They answer the call.

But before they can protect others, they must take responsibility for their own health.

Strong body.

Healthy physiology.

Resilient mind.

Prepared professional.

Protected community.

PHYSTA® TONGKAT ALI

Clinically researched. Standardized. Science-led.

FOR THE PERSON.

FOR THE PERFORMANCE.

FOR THE RESPONSIBILITY.

FOR MALAYSIA.

 

Science First. Everything Follows.

The People Behind the uniform

https://web.biotropicsmalaysia.com/zul  

Nu-Prep  60s

https://s.shopee.com.my/1qYnsXZfWj

Nu-Prep Twin Pack 60s

https://s.shopee.com.my/3qJsGIfmIG 

PHYSTA® — FROM 26 CLINICAL STUDIES TO AN EVIDENCE MATRIX. MERDEKA !

PHYSTA® — FROM 26 CLINICAL STUDIES TO AN EVIDENCE MATRIX

The scientific story. Testosterone Management.

MERDEKA, MERDEKA, MERDEKA

For more than 69 years, Malaysia has progressed from independence to building its own scientific and technological capability.

 

Tongkat Ali, Eurycoma longifolia, represents an especially interesting Malaysian example:

Traditional Malaysian knowledge → botanical resource → standardized extraction → analytical chemistry → quality control → human clinical research → evidence-based application.

 

That progression is what makes “Science First, Everything Follows” a meaningful positioning.

The key scientific issue is not simply whether a supplier can sell Eurycoma longifolia or even report a certain eurycomanone percentage.

 

The real question is:

Does the material being purchased reproduce the identity, chemical standardization, manufacturing characteristics, safety profile and clinically investigated material?

 

That is where the 26-study evidence base becomes important.

 

1. THE FOUR-PARAMETER STANDARDIZATION

Biotropics states that PHYSTA® is standardized using four characteristic parameters:

 

PARAMETER	SCIENTIFIC ROLE
Eurycomanone	Important quassinoid chemical marker
Total protein/peptides	Part of the standardized extract profile
Glycosaponins	Characteristic phytochemical fraction
Polysaccharides	Part of the standardized extract profile

 

Biotropics also states that PHYSTA® contains more than 65 compounds, meaning eurycomanone is a marker—not a complete chemical description of the extract.

https://z.biotropicsmalaysia.com/

This is a crucial distinction for your proposed evidence matrix:

Eurycomanone ≠ PHYSTA®

A supplier could theoretically match the eurycomanone number but still produce an extract with a different overall chemical profile.

 

Therefore:

Single-marker matching is weaker evidence than multi-parameter standardization.

 

2. THE 26-STUDY MATRIX SHOULD BE STRUCTURED BY EVIDENCE LEVEL

 

I recommend using five evidence columns, rather than simply “study name / result.”

A. Clinical question

What was the study actually trying to determine?

B. Population

Who was studied?

Men? Women? Ageing adults? Infertile men? Moderately stressed adults?

C. Intervention

What exact material and dose were used?

This is extremely important.

D. Endpoint

What was objectively measured?

Testosterone? Free testosterone? cortisol? sperm motility? MENQOL? muscle strength? immune markers?

E. Evidence strength

RCT / placebo-controlled / open-label / pilot / observational / preclinical.

 

This prevents very different studies from being presented as if they have identical evidentiary weight.

 

3. EXAMPLE OF THE EVIDENCE MATRIX

Based on the studies I could independently verify, the matrix begins like this:

Evidence area	Study / population	Design	INTERVENTION	MAIN FINDING	EVIDENCE WEIGHT
Testosterone/ ageing	105 men, 50-70	Randomized, double-blind, placebo-controlled, multicentre	PHYSTA® 100/200 mg/day, 12 weeks	↑ total testosterone; 200 mg also reduced cortisol and improved strength/QoL	High
Sexual health / QoL	109 men, 30–55	Randomized, double-blind, placebo-controlled	PHYSTA® 300 mg/day, 12 weeks	Improvements in physical functioning, erectile function, libido and semen parameters	High
Andropause / late-onset hypogonadism	76 men	Open-label	PHYSTA® 200 mg/day, 4 weeks	PHYSTA® 200 mg/day, 4 weeks Reported improvements in testosterone status and ageing-male symptoms	Moderate–low
Male infertility	75 men with idiopathic infertility	Clinical intervention	PHYSTA® 200 mg/day, 3 months	Improvements reported in sperm concentration, motility and morphology; spontaneous pregnancies reported	Moderate
Immune function	Middle-aged adults	Randomized, double-blind, placebo-controlled	PHYSTA® 200 mg/day, 4 weeks	Changes in CD4+ T cells and other immune parameters	High
Stress / mood	Moderately stressed adults	Randomized placebo-controlled	PHYSTA® + multivitamins	Reduced stress and improved quality-of-life measures	Moderate–high
Strength / exercise	Middle-aged men with androgen-deficiency symptoms	Randomized, double-blind, placebo-controlled	PHYSTA® 200 mg/day + exercise	Greater improvement in strength than exercise alone	High
Menopause	138 women, 40–55	Randomized, double-blind, placebo-controlled	PHYSTA® 50/100 mg/day, 12 weeks	100 mg group showed significant improvement in total MENQOL and physical/sexual domains	High
Microbiome	55-year-old woman	Case study	PHYSTA® 100 mg/day, 30 days	Changes in microbial diversity and selected bacterial populations	Microbiome Very preliminary
Metabolic mechanisms	Cell/animal models	Preclinical	PHYSTA®	Insulin secretion/glucose uptake and nephroprotective findings	Preclinical-not clinical efficacy

 

The testosterone RCT is particularly useful because it was registered, randomized, double-blind and placebo-controlled; PubMed reports that the 200 mg group had significant total-testosterone improvement, reduced cortisol and increased muscle strength, with no clinically relevant safety changes.

PubMed https://pubmed.ncbi.nlm.nih.gov/34262417/

The 109-man randomized trial is also independently available through PubMed/PMC and reported improvements in physical functioning and erectile-function measures, with semen-related outcomes and comparable safety parameters.

PubMed Central (PMC) +1 https://pmc.ncbi.nlm.nih.gov/articles/PMC3518798/?utm_source=chatgpt.com

 

The immune study was likewise randomized, double-blind and placebo-controlled.

PubMed https://pubmed.ncbi.nlm.nih.gov/26816234/

 

And the 2025 menopause study is particularly significant for your broader men + women scientific story: 138 women aged 40–55 were randomized to 50 mg, 100 mg or placebo; the 100 mg group had a statistically significant reduction in total MENQOL and improvements in physical and sexual domains.

PubMed Central (PMC) +1 https://pubmed.ncbi.nlm.nih.gov/41283187/

 

4. THE MOST IMPORTANT MATRIX: “MATERIAL → STANDARDIZATION → CLINICAL RESULT”

This is where I think your presentation can become much stronger.

Instead of saying:

“26 studies prove Tongkat Ali works.”

say:

“The 26-study evidence base must be interpreted together with the identity and standardization of the material that was actually investigated.”

Then create this chain:

BOTANICAL IDENTITY

↓

Eurycoma longifolia

EXTRACTION

↓

Standardized aqueous root extract

CHEMICAL STANDARDIZATION

↓

Eurycomanone

protein/peptides

glycosaponins

polysaccharides

BATCH QUALITY

↓

COA + analytical testing + contaminant testing + manufacturing controls

CLINICAL INVESTIGATION

↓

Randomized / placebo-controlled / open-label / pilot studies

HUMAN ENDPOINTS

↓

Testosterone

Stress

Cortisol

Sexual health

Fertility

Strength

Quality of life

Menopause

Immune parameters

EVIDENCE-BASED POSITIONING

That is far more defensible than using eurycomanone alone.

 

5. WHY A CHEAPER CHINESE EXTRACT CANNOT SIMPLY “INHERIT” THE 26 STUDIES

This is perhaps the strongest commercial/scientific message.

Imagine two extracts:

Extract A

Eurycomanone = 1.0%

PHYSTA®

Eurycomanone = 1.0%

It would be scientifically incorrect to conclude:

“Both are therefore clinically equivalent.”

Why?

Because the clinical evidence follows the investigated material, not merely the name of the plant or one analytical marker.

The 109-man clinical study specifically investigated a freeze-dried water extract identified as PHYSTA®. �

PubMed Central (PMC)

The 2021 testosterone study likewise specifically investigated standardized aqueous-root PHYSTA®. �

PubMed

And the menopause RCT explicitly describes the study product as standardized PHYSTA® water extract manufactured, packaged and registered by the study sponsor. �

PubMed Central (PMC)

Therefore:

A COA can demonstrate what a new batch contains.

It cannot transfer somebody else's clinical results onto that batch.

That is a very powerful scientific principle.

 

6. COA — IMPORTANT, BUT NOT THE WHOLE EVIDENCE

I would therefore position COA as one layer of the evidence pyramid:

LEVEL 1 — IDENTITY

Is it genuinely Eurycoma longifolia?

LEVEL 2 — PURITY

Is it free from unacceptable contaminants/adulteration?

LEVEL 3 — STANDARDIZATION

Does it meet the defined chemical specifications?

LEVEL 4 — BATCH CONSISTENCY

Does batch after batch remain within specification?

LEVEL 5 — MANUFACTURING CONTROL

Is the extraction/manufacturing process controlled?

LEVEL 6 — SAFETY

Is there toxicological and human safety evidence?

LEVEL 7 — CLINICAL EVIDENCE

Has the actual standardized material been tested in humans?

LEVEL 8 — REPRODUCIBILITY

Can the clinical findings be reproduced across populations, studies and settings?

That is the real scientific hierarchy.

 

7. ONE VERY IMPORTANT CORRECTION TO THE “26 STUDIES” MESSAGE

I would not call all 26 studies equivalent clinical trials.

Biotropics' current page says PHYSTA® is supported by 26 clinical studies, but the same page also contains different evidence types—including randomized controlled trials, open-label studies, a case study and preclinical investigations. �

biotropicsmalaysia.com +1

For credibility, your master document should therefore classify every study as:

RCT / controlled clinical / open-label / pilot / case study / observational / preclinical.

That actually strengthens the story because it shows scientific transparency.

🇲🇾 THE FINAL STORY

69 YEARS OF MERDEKA.

NOW, LET SCIENCE SPEAK.

Malaysia's independence gave us the freedom to build our own future.

Our biodiversity gave us the raw material.

Traditional knowledge gave us the starting point.

But science gave us the methodology to investigate it.

With Eurycoma longifolia, the journey moves from:

Forest → Root → Extraction → Standardization → COA → Laboratory → Clinical Trial → Human Evidence → Global Science.

And the lesson is simple:

A plant name is not a clinical result.

A single marker is not an entire extract.

A COA is not a clinical trial.

A cheap copy cannot automatically inherit another ingredient's evidence.

The real scientific value lies in controlling the entire chain.

Identity.

Standardization.

Quality.

Consistency.

Safety.

Clinical evidence.

And when those pieces come together, we move beyond traditional claims.

We move into evidence-based Malaysian science.

 

 

MALAYSIA — SCIENCE FIRST. EVERYTHING FOLLOWS.

69 years of Merdeka.

From Malaysian biodiversity to clinical science.

From traditional knowledge to evidence.

From Malaysia - to the world.

 

MERDEKA! MERDEKA! MERDEKA!  

https://web.biotropicsmalaysia.com/zul